Mer­ck CEO in­di­cates in­ter­est in GLP-1 com­bi­na­tion ther­a­pies, may pur­sue deals

Not want­i­ng to be left out in the cold, Mer­ck now plans to pur­sue GLP-1 com­bi­na­tion ther­a­pies amid grow­ing ex­cite­ment about the lu­cra­tive po­ten­tial of a drug class that may treat a wide range of con­di­tions.

CEO Rob Davis de­scribed the drug­mak­er’s in­ter­est on Thurs­day at the Gold­man Sachs Health­care C-suite Un­script­ed Con­fer­ence, re­spond­ing to a ques­tion about the role of GLP-1s in the broad­er meta­bol­ic space. Mer­ck is look­ing for reg­i­mens in­ter­nal­ly and through a “busi­ness de­vel­op­ment per­spec­tive” that not on­ly shows weight loss im­prove­ments but al­so ben­e­fits in oth­er ar­eas like heart dis­ease and fat­ty liv­er dis­ease, Davis said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER